Clinical Trial Detail

NCT ID NCT03425006
Title Pembrolizumab and Itacitinib (INCB039110) for NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors University of Pennsylvania
Indications

lung non-small cell carcinoma

Therapies

Itacitinib + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST